MMRF Announces 2018 Endurance Run/Relay to Advance Multiple Myeloma Research to Improve the Lives of Patients

NORWALK, Conn., Aug. 27, 2018 /PRNewswire/ -- The Multiple Myeloma Research Foundation (MMRF) today announced the next evolution in one of its signature endurance programs, The Journey Towards a Cure, in support of patients with multiple myeloma. This event previously centered on the efforts of one remarkable patient advocate, Eric Gelber, and his mission to run 200 miles in Central Park, New York City (NYC) over the course of one weekend. This program will now further extend its reach to the entire community, offering a unique opportunity to join the Journey.

Eric has raised over $1,100,000 to support cutting-edge research in the field of multiple myeloma initiated by the MMRF. These funds enable the MMRF to pioneer an innovative precision medicine research model that accelerates important potential new lifesaving treatments for patients with multiple myeloma.

"I've always questioned what is possible and what I am willing to do to support patients with this incurable blood cancer," said Eric Gelber, patient advocate, ultramarathoner and The Journey Towards a Cure creator. "I know by supporting the MMRF, funds will be used to advance their research and ultimately bring a cure to every patient."

The first annual The Journey Towards a Cure 12 Hour Endurance Run/Relay will feature individuals or relay teams running and/or walking as many miles as possible over a 12-hour period on October 6^th on Randall's Island Park, NYC. Sponsors of the event include Celgene Corporation, Club Fit, Drymax and Dick's Sporting Goods.  

Those interested in starting their Journey can visit https://endurance.themmrf.org/JourneyRunRelay to sign up.

"The expansion of this event now encompasses participants with a range of abilities including walkers, runners and ultra-marathoners," said Jane Hoffmann, Associate Director, Endurance Events for the MMRF. "This race is an opportunity for both individuals and teams to take on an intensely personal challenge and push themselves beyond what they believed possible – all with an important goal of helping to find a cure for multiple myeloma."

About Multiple Myeloma 
Multiple myeloma is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 30,000 adults will be diagnosed this year and 12,500 people are predicted to die from the disease.

About the Multiple Myeloma Research Foundation (MMRF)  
The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $400 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.

Contacts:      
Michelle Fusco
Marketing Director
The Multiple Myeloma Research Foundation
203-652-0229 
[email protected]

SOURCE Multiple Myeloma Research Foundation

Related Links

http://www.themmrf.org